Eylea Industry Analysis for US, 5EU and Japan & 2022 MCD Forecasts

1
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to
2022byGlobalData

• Explore all reports for
•  Diabetes Therapeutics market _at_
  http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/diabetes-therape
  utics .

2
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• The report Eylea (Microvascular Complications of
  Diabetes) Forecast and Market Analysis to 2022?
  by GlobalData is now available at
  RnRMarketResearch.com.
• Contact sales_at_rnrmarketresearch.com with Eylea
  (Microvascular Complications of Diabetes)
  Forecast and Market Analysis to 2022 in subject
  line and your contact details to purchase this
  report or get your questions answered.
• The entire market for microvascular complications
  of diabetes (MCD) diabetic nephropathy,
  retinopathy, and neuropathy is facing an
  extremely high level of unmet need across the 7MM
  (US, 5EU and Japan). Despite its enormous
  potential, the MCD market is facing the major
  global barrier in the sparsely populated
  pipeline. The diabetic retinopathy segment of the
  market has recently seen rapid uptake of novel
  anti-VEGF therapies and is experiencing a strong
  growth. On the other hand, the diabetic
  neuropathy and nephropathy segments face the
  barrier in and increasing number of generic
  competitors.
• Buy a copy of this report by GlobalData _at_
  http//www.rnrmarketresearch.com/contacts/purchase
  ?rname147161 .

3
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• Eylea is a fusion protein consisting of
  VEGF-binding portions. It is specifically
  designed to bind to all isoforms of VEGF-A,
  VEGF-B and placental growth factor (PGF), leading
  to their removal from circulation. Decrease in
  VEGF-A levels causes a decrease in macular edema
  by restricting the growth of new blood vessels.
• Scope
• Overview of MCD, including epidemiology,
  etiology, symptoms, diagnosis, pathology and
  treatment guidelines as well as an overview on
  the competitive landscape.
• Detailed information on Eylea including product
  description, safety and efficacy profiles as well
  as a SWOT analysis.
• Sales forecast for Eylea for the top seven
  countries from 2012 to 2022.
• Sales information covered for the US, France,
  Germany, Italy, Spain, the UK and Japan.

4
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return
• Stay ahead of the competition by understanding
  the changing competitive landscape for MCD
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Eylea
  performance
• Obtain sales forecast for Eylea from 2012-2022 in
  top seven countries (the US, France, Germany,
  Italy, Spain, the UK and Japan)
• Complete report spread across 75 pages available
  _at_ http//www.rnrmarketresearch.com/eylea-microvasc
  ular-complications-of-diabetes-forecast-and-market
  -analysis-to-2022-market-report.html .
• Read more on Eylea (Microvascular Complications
  of Diabetes) Forecast and Market Analysis to
  2022 report below.

5
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• Table Of Contents
• 1 Table of Contents1 Table of Contents 61.1
  List of Tables 91.2 List of Figures 9
• 2 Introduction 102.1 Catalyst 102.2 Related
  Reports 11
• 3 Disease Overview 133.1 Etiology and
  Pathophysiology 153.1.1 Diabetic Nephropathy
  153.1.2 Diabetic Retinopathy 173.1.3 Diabetic
  Neuropathy 183.2 Prognosis 193.3 Quality of
  Life 203.4 Symptoms 21
• 4 Disease Management 224.1 Treatment Overview
  224.1.1 Diagnosis and Referrals 224.1.2
  Screening 244.1.3 Treatment Guidelines 25

6
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• 5 Competitive Assessment 335.1 Overview 335.2
  Strategic Competitor Assessment 34
• 6 Opportunity and Unmet Need 386.1 Overview
  386.2 Unmet Needs 396.2.1 Unified Treatment for
  the Microvascular Complications of Diabetes
  396.2.2 Optimization of Personalized Therapy in
  the Microvascular Complications of Diabetes
  396.2.3 Treatment for Diabetic Nephropathy that
  Would Prevent ESRD 416.2.4 Cardio- and
  Renoprotective Therapy for Diabetic Nephropathy
  426.2.5 Efficient Therapy for Retinopathy
  436.2.6 Convenient Administration in Diabetic
  Retinopathy Treatment 436.2.7 Treatment for
  Diabetic Neuropathy 446.3 Unmet Needs Gap
  Analysis 456.4 Opportunity Therapy for the
  Underlying Cause of the Microvascular
  Complications of Diabetes 476.5 Opportunity
  Patient-Tailored Therapy for the Microvascular
  Complications of Diabetes 476.6 Opportunity
  Efficacious Therapy for Diabetic Nephropathy
  486.7 Opportunity Topical Treatment for
  Diabetic Retinopathy 48

7
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• 7 Pipeline Assessment 507.1 Overview 507.2
  Promising Drugs in Clinical Development 52
• 8 Eylea (aflibercept) 548.1 Overview 548.2
  Efficacy 568.3 Safety 578.4 Dosing and
  Formulation 578.5 Potential Clinical Positioning
  578.6 Potential Commercial Positioning 588.7
  Pricing and Reimbursement 588.8 SWOT Analysis
  598.9 Forecast 59
• 9 Appendix 619.1 Bibliography 619.2
  Abbreviations 659.3 Methodology 679.4
  Forecasting Methodology 679.4.1 Diagnosed
  Patients 679.4.2 Percent Drug-Treated Patients
  689.4.3 General Pricing Assumptions 689.4.4
  Generic Erosion 699.4.5 Pricing of Pipeline
  Agents 69

8
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• List of Tables
• Table 1 Risk Factors for MCD 15Table 2
  Symptoms of MCD 21Table 3 Diagnostic Tests and
  Typical Criteria for MCD 23Table 4 Treatment
  Guidelines for MCD 26Table 5 Most Prescribed
  Drugs for MCD by Class in the 7MM, 2012 29Table
  6 Leading Drug Treatments for MCD, 2013 36Table
  7 Overall Unmet Needs - Current Level of
  Attainment 38Table 8 Clinical Unmet Needs in
  MCD - Gap Analysis, 2012 46Table 9 MCD - Phase
  Pipeline, 2013 52Table 10 Comparison of Drugs
  in Development for MCD, 2013 53Table 11 Product
  Profile - Eylea 55Table 12 Eylea SWOT Analysis,
  2013 59Table 13 Global Sales Forecasts (m) for
  Eylea, 2012-2022 60Table 14 Number of
  High-Prescribing Physicians Surveyed 71
• List of Figures
• Figure 1 Potential Mechanisms of
  Diabetes-Induced Microvascular Complications
  14Figure 2 General Treatment Algorithms for MCD
  27Figure 3 Competitive Assessment of Late-Stage
  Pipeline Agents in MCD, 2012-2022 53

9
Eylea (Microvascular Complications of Diabetes)
Forecast and Market Analysis to 2022

• For further information on Eylea (Microvascular
  Complications of Diabetes) Forecast and Market
  Analysis to 2022 report OR for any other
  business research / market intelligence need on
  the Diabetes Therapeutics market _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/diabetes-therape
  utics .
• Contact sales_at_rnrmarketresearch.com
• OR
• Call 1 888 391 5441.

10
Eloctate (Hemophilia A and B) Forecast and
Market Analysis to 2022

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.